PT - JOURNAL ARTICLE AU - Petrone, Mary E. AU - Lucas, Carolina AU - Menasche, Bridget AU - Breban, Mallery I. AU - Yildirim, Inci AU - Campbell, Melissa AU - Omer, Saad B. AU - Ko, Albert I. AU - Grubaugh, Nathan D. AU - Iwasak, Akiko AU - Wilen, Craig B. AU - Vogels, Chantal B.F. AU - Fauver, Joseph R. TI - Insights into the limited global spread of the immune evasive SARS-CoV-2 variant Mu AID - 10.1101/2022.03.28.22273077 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.28.22273077 4099 - http://medrxiv.org/content/early/2022/03/30/2022.03.28.22273077.short 4100 - http://medrxiv.org/content/early/2022/03/30/2022.03.28.22273077.full AB - SARS-CoV-2 ‘Variants of Concern’ (VOCs) continue to reshape the trajectory of the COVID-19 pandemic. However, why some VOCs, like Omicron, become globally dominant while the spread of others is limited is not fully understood. To address this question, we investigated the VOC Mu, which was first identified in Colombia in late 2020. Our study demonstrates that, although Mu is less sensitive to neutralization compared to variants that preceded it, it did not spread significantly outside of South and Central America. Additionally, we find evidence that the response to Mu was impeded by reporting delays and gaps in the global genomic surveillance system. Our findings suggest that immune evasion alone was not sufficient to outcompete highly transmissible variants that were circulating concurrently with Mu. Insights into the complex relationship between genomic and epidemiological characteristics of previous variants should inform our response to variants that are likely to emerge in the future.Competing Interest StatementNDG and JRF are paid consultants for Tempus Labs, and NDG is a paid consultant for the National Basketball Association for work related to COVID-19 but is outside the submitted work. IY reported being a member of the mRNA-1273 Study Group and has received funding to her institution to conduct clinical research from Pfizer and Moderna outside the submitted work.Funding StatementThis work was supported in part by a Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University and the Centers for Disease Control and Prevention (CDC) Broad Agency Announcement # 75D30120C09570 awarded to NDG. CBW is funded by Burroughs Wellcome Fund and BM is funded through an NIH T32 HL 007974.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yale Human Research Protection Program Institutional Review Board (IRB Protocol ID 2000028924). Informed consent was obtained from all enrolled vaccinated health care workers.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll SARS-CoV-2 genomic data from this manuscript has been made publicly available on GISAID.